ABL1 L364I

CI-VAR-00002340Explore in graph →NP_005148.2:p.Leu364IleNM_005157.5:c.1090C>ACIViC 1508

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Chronic Myeloid Leukemia, BCR-ABL1 Positive4
BCR::ABL1 Fusion AND ABL1 L364I	Dasatinib	Predictive	C	Does Not Support Resistance	3	accepted	EID4434 Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with the L364I secondary variant in 9/12 bacterial clones generated … (full text at CIViC) PMID 16775234 · Talpaz et al., 2006 · Open in CIViC	civic
BCR::ABL1 Fusion AND ABL1 L364I	Dasatinib	Predictive	C	Supports Sensitivity Response	2	submitted	EID4485 In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.